Guerbet
| Industry | Pharmaceutical |
|---|---|
| Founded | 1926 |
| Headquarters | Villepinte |
| Revenue | € 0.489 billion (2015) |
Number of employees | 2,500 (2015) |
| Website | www.guerbet.com |
Guerbet is a research-centered pharmaceutical company based in France that is one of the major players in the contrast agents business.
The company's main products are:
- Dotarem (Gadoteric acid) - MRI Contrast agent. Launched on the French market in 1989, Dotarem® is currently available in over 70 countries.
- Xenetix (Iobitridol) - X-ray Contrast agent. In 1994 Xenetix® obtained its first marketing authorization in France. Originally packaged in vials, it has also been available since 2006 in the form of a polypropylene softbag, known as ScanBag® by Xenetix®. Xenetix® is present in 68 countries and continues to expand in Asia and South America.
- Lipiodol (Iodinated ethyl esters of fatty acids of poppyseed oil) - IRT X-ray Contrast agent. Discovered by Marcel Guerbet in 1901, Lipiodol® was the first iodinated contrast agent used in the world. It was first used in radiology in France in 1921.
- FlowSens - Injection solution for contrast media and saline injection in CT medical imaging
History
The company is named after the French chemist Marcel Guerbet (1861–1938), who produced Lipiodol in 1901 and his son André Guerbert, who founded the company in 1926. The X-ray contrast properties of Lipiodol were discovered in 1918.
On July 27, 2015, Guerbet announced that it has entered into a definitive agreement under which it will acquire Mallinckrodt’s contrast media and delivery systems business ("CMDS").
On November 27, 2015, Guerbet completed acquisition of Mallinckrodt’s Contrast Media and Delivery Systems business ("CMDS"), for $270M in cash, financed by BNP Paribas.[1]